SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.
SignaCor has raised $332K in total funding. The most recent round was Seed. The last funding was announced in March 2026.
SignaCor's investors include Zinc.
SignaCor is headquartered in Belfast, United Kingdom.
SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.
SignaCor is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SignaCor — Funding & Investors." VCBacked, March 9, 2026, https://www.vcbacked.co/company/signacor. Accessed September 30, 2026.
VCBacked. (2026). SignaCor — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/signacor
{{cite web |title=SignaCor — Funding & Investors |url=https://www.vcbacked.co/company/signacor |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated